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Prevalence of glycometabolic disturbances in patients with a suspected acute
coronary syndrome is high (Chapter 2). One in three patients has signs of
disturbed glucose metabolism and this condition is associated with previous or
newly diagnosed coronary artery disease.
In Chapter 3.1, we found that the prognostic impact of admission hyperglycaemia
in 522 patients with a suspected acute coronary syndrome was greater than long-
term glucose dysregulat ion. Patients with higher admission glucose (7.8 - 11.0 or
> 11.1 mmol/L) had significantly higher mortality (9Yo and 21%) as compared to
patients with normal glucose levels (6%). Mortality in patients with elevated
Hbal C (> 6.2%) was not significantly higher (8% vs. 12Yo). Probably, apart from a
sign of glycometabolic dysregulation, admission hyperglycaemia is also a
symptom of stress and a more sick patient population. ln Chapter 3.2 the
prognostic importance of admission glucose in 356 non-diabetic patients with ST-
elevation myocardial infarction (STEMI) was described. Patients with elevated
admission glucose (7.8 - 11.0 or > 11.1 mmol/L) had a larger enzymatic infarct
size, a lower left ventricular ejection fraction and a higher long-term mortality. ln
patients with diabetes (Ghapter 3.3), long-term mortality after STEMI was
significantly higher when compared to patients without diabetes, despite the use
of reperfusion therapy. The increased mortality in patients with diabetes after
STEMI was mainly due to heart failure, whereas the occurrence of sudden death
was comparable between patients with and without diabetes. Although there was
only a small number of diabetic patients in this study, primary percutaneous
coronary intervention (PCl) seemed preferable to thrombolysis. In Chapter 3.4
the prognosis of patients with diabetes with non-STEMI was assessed. After non-
STEMf, patients with diabetes (n=1677) had a higher mortality compared to
patients without diabetes (n=6123): one-year mortality was 13.5o/o in patients with
diabetes compared to 6.9% in those without diabetes. Further risk stratification i
diabetic patients is possible according to the presence of clinical risk-indicators,
ST-depression on admission and the measurement of biomarkers such as
troponin, Nt-proBNP and interleukin-6. In Ghapter 4.1 it was demonstrated that
STEMI patients (n=460) with admission hyperglycaemia measured before
reperfusion therapy, more often had impaired epicardial flow of the infarct related
artery compared to patients with normoglycaemia. Antegrade epicardial flow
before reperfusion was present in 28% of the patients with normoglycaemia
compared to 12o/o f patients with hyperglycaemia. Furthermore, when epicardial
reperfusion had been achieved through primary PCl, myocardial flow was
disturbed in patients with diabetes (Ghapter 4.2). Good myocardial blush (90%
vs. 80%) and complete ST-segment resolution (65% vs. 45o/o) as signs of
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Summary and conclusions
restored myocardial perfusion were more often observed in patients without
diabetes (n=322) compared to patients with diabetes (n=64). Chapter 4.3 showed
that both elevated erythrocyte sedimentation rate (ESR) and admission glucose
were independent predictors of long-term mortality in STEMI patients treated with
reperfusion therapy. There was, however, no association or interaction between
glucose levels and the inflammatory response as reflected by ESR.
In Ghapter 5.1 results were presented of a meta-analysis of randomised trials
comparing thrombolysis with primary PCl. lt was shown that the beneficial effects
of primary PCI compared to thrombolysis in diabetic patients with STEMI (n=947)
were at least equal to the effects in patients without diabetes (n= 5368). Primary
PCI resulted in a 50% reduction of 30-day mortality in patients with diabetes
(6.1% vs. 11.60/0) and a 30Yo reduction in patients without diabetes (4.9% vs.
7.0o/o). Although the relative risk reduction of primary PCI in diabetic and non-
diabetic patients is comparable, the absolute risk reduction is much greater in
diabetic patients. In Ghapter 5.2 it was made clear that intervention in glucose
metabolism through administration of glucose - insulin - potassium (GlK) was
associated with a small reduction in 3-year mortality (9.7To vs. 11.2To) in STEMI
patients (n=940) treated with primary PCl. However, in patients without signs of
heart failure on admission, the initial beneficial effect of GIK administration was
sustained during long-term follow-up (5.4% vs. 9.5%). The rationale of the GIPS -
ll study was described in Ghapter 5.3. The GIPS - ll study aimed to confirm the
beneficial effects of GIK administration in STEMI patients without heart failure
treated with reperfusion therapy. In Ghapter 5.4 however, it was shown that the
GIPS - ll study did not confirm the beneficial effect of GIK intervention as found in
the subgroup analysis of the GIPS - l. Intervention with GIK in STEMI patients
(n=858) without signs of heart failure treated with reperfusion therapy, did not
result in a reduced 30-day mortality (2.9To vs. 1.8o/o, OR 1.6; p=0.27) or a
reduction in enzymatic infarct size (2008 t 1930 vs. 1932 ! 1847 U/1, p=9.53;
compared to patients not treated with GlK.
Final comments
The prevalence of diabetes has increased dramatically in the past 50 years and it
is estimated that approximately one in three persons born in 2000 will develop
diabetes at some point in their lifetime 11,21. As a sharp rise in the number of
diabetic patients presenting with cardiovascular disease is expected, it is of the
utmost importance to improve outcome of this high-risk patient group. Moreover,
one must acknowledge that glycometabolic disease in non-diabetic patients is
also associated with a risk for cardiovascular disease and patients presenting with
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